Skip to content
Back to Rare Disease Venture Atlas Agent

Card snapshot

rare-disease-atlas.github.io · 2026-11-22 14:39:59 UTC · 7491a492b0b9e128db5f1195e513ae98a6f7ccd7798a1bd5e7ca3ac3c922ddbf

This is a frozen copy of the agent's agent-card.json as we observed it at the timestamp above. We capture a new snapshot every time the card's content hash changes. Useful for: forensic drift analysis, verifying downstream callers see the right version, reproducing routing decisions made historically.

{
  "name": "Rare Disease Venture Atlas Agent",
  "description": "Open translational & venture diligence specialist agent anchored on Paired Myelofibrosis Flagships\u2014Clonal JAK2 V617F+ Primary Myelofibrosis (JH2 vs JH1 allosteric selectivity, mutant CALR) and Reversible JAK2-Negative Autoimmune Myelofibrosis (AIMF, 74-80% marrow fibrosis reversal + dual transfusional & IL-6/hepcidin/ferroportin iron overload)\u2014plus stateless hypothesis red-teaming (POST /api/stress-test), MyelofibrosisBench-v1, Hugging Face Parquet tables, non-dilutive grant stacks, 90-day validation plans, and live federated diligence across all 7,000+ orphan diseases.",
  "url": "https://api.rare-disease-atlas.workers.dev/a2a",
  "documentationUrl": "https://rare-disease-atlas.github.io/llms-full.txt",
  "mcpServerUrl": "https://api.rare-disease-atlas.workers.dev/mcp",
  "mcpServerCardUrl": "https://rare-disease-atlas.github.io/.well-known/mcp/server-card.json",
  "x402ManifestUrl": "https://rare-disease-atlas.github.io/.well-known/x402.json",
  "citationUrl": "https://rare-disease-atlas.github.io/CITATION.cff",
  "provider": {
    "organization": "Rare Disease Venture Atlas",
    "url": "https://rare-disease-atlas.github.io"
  },
  "version": "1.6.0",
  "protocolVersion": "0.3.0",
  "preferredTransport": "JSONRPC",
  "x402": {
    "paymentRequired": false,
    "priceUsd": "0"
  },
  "erc8004": {
    "status": "ready",
    "trustModel": "open-science-public-good"
  },
  "capabilities": {
    "streaming": false,
    "pushNotifications": false,
    "stateTransitionHistory": false
  },
  "defaultInputModes": [
    "text/plain",
    "application/json"
  ],
  "defaultOutputModes": [
    "text/plain",
    "application/json"
  ],
  "skills": [
    {
      "id": "jak2-clonal-myelofibrosis-diligence",
      "name": "Clonal JAK2 V617F+ Myelofibrosis (JH2 vs JH1) Translational Diligence",
      "description": "Analyzes Type I JH1 JAK inhibitor cytopenia & persistence failure modes, mutant-selective JH2 pseudokinase binders/degraders (INCB160058 NCT06313593, PDB 4FVR/6E2Q/8BAK vs WT 4FVP), Type II persistence breakers (AJ1-11095 NCT06343805), mutant CALR biologics, and single-cell bone marrow datasets (GSE144568, GSE122198).",
      "tags": [
        "myelofibrosis",
        "JAK2-V617F",
        "JH2",
        "JH1",
        "CALR",
        "PROTAC",
        "clinical-trials"
      ],
      "examples": [
        "Explain JH2 vs JH1 selectivity in JAK2 V617F myelofibrosis and active NCT trials.",
        "Call get_disease_case_study for jak2-myelofibrosis and design a zero-wet-lab JH2 degrader validation plan."
      ]
    },
    {
      "id": "autoimmune-myelofibrosis-iron-triage",
      "name": "Reversible Autoimmune Myelofibrosis (AIMF) & Dual Iron Overload Positive-Control Triage",
      "description": "Contrasts clonal JAK2+ PMF against reversible JAK2-negative lupus/autoimmune myelofibrosis (AIMF: 74-80% hematologic & marrow fibrosis remission on corticosteroids/rituximab) and dual transfusional + IL-6/hepcidin/ferroportin reticuloendothelial iron overload.",
      "tags": [
        "autoimmune-myelofibrosis",
        "AIMF",
        "lupus",
        "SLE",
        "hepcidin",
        "ferroportin",
        "iron-overload",
        "fibrosis-reversal"
      ],
      "examples": [
        "How does JAK2-negative autoimmune myelofibrosis (AIMF) with lupus suspicion and dual iron overload differ from triple-negative PMF?",
        "Use AIMF as Nature's Positive Control to identify human marrow fibrosis reversal switches."
      ]
    },
    {
      "id": "stress-test-orphan-hypothesis",
      "name": "Stateless Orphan Hypothesis Red-Team & Biological/Venture Stress-Test",
      "description": "Red-teams candidate drug targets, structural ML binders, diagnostic triage classifiers, or orphan venture theses via POST https://api.rare-disease-atlas.workers.dev/api/stress-test against JH2 vs JH1 selectivity traps, AIMF vs Triple-Negative PMF pathology discordance, Phase 3 endpoint casualties (TRANSFORM-1, IMpactMF), MyelofibrosisBench-v1, and FY2026 FDA Orphan unit economics.",
      "tags": [
        "stress-test",
        "red-team",
        "hypothesis-validation",
        "myelofibrosis",
        "AIMF",
        "JAK2-V617F",
        "MyelofibrosisBench-v1"
      ],
      "examples": [
        "Stress-test a mutant-selective JAK2 V617F JH2 PROTAC degrader hypothesis via POST https://api.rare-disease-atlas.workers.dev/api/stress-test.",
        "Red-team an EHR + WSI diagnostic triage wedge separating lupus-associated Autoimmune Myelofibrosis from Triple-Negative PMF."
      ]
    },
    {
      "id": "search-orphan-venture-wedges",
      "name": "Search Orphan Disease Startup Blueprints & 90-Day Validation Plans",
      "description": "Searches concrete rare-disease startup wedges via search_founder_opportunities and generates 30/60/90-day killer-experiment roadmaps via get_90_day_validation_plan across AI/ML drug repurposing, public-health/EHR diagnostics, and venture-philanthropy spinouts.",
      "tags": [
        "rare-disease",
        "venture",
        "biotech",
        "ai-bio",
        "public-health",
        "90-day-plan"
      ],
      "examples": [
        "Search zero-wet-lab computational AI/ML startup wedges under $250K seed budget and generate a 90-day validation plan.",
        "What public-health diagnostic wedges prevent misdiagnosis of Autoimmune Myelofibrosis?"
      ]
    },
    {
      "id": "federated-7000-orphan-disease-scan",
      "name": "Live 7,000-Orphan-Disease Federated Diligence Scan",
      "description": "Queries OpenTargets Platform v4, ClinicalTrials.gov v2, and PubMed live via search_any_orphan_indication for any of 7,000+ orphan diseases, pairing FY2026 FDA Orphan Drug ($4,682,003 PDUFA waiver, 7-yr exclusivity) and Rare Pediatric PRV unit economics against Paired Myelofibrosis Flagships.",
      "tags": [
        "orphan-drug",
        "7000-diseases",
        "OpenTargets",
        "ClinicalTrials",
        "PubMed",
        "PRV",
        "diligence"
      ],
      "examples": [
        "Run search_any_orphan_indication on VEXAS syndrome and Telomere Biology Disorders and benchmark against JAK2 V617F+ and Autoimmune Myelofibrosis.",
        "Evaluate live clinical trial gaps and Rare Pediatric PRV eligibility for Duchenne muscular dystrophy."
      ]
    },
    {
      "id": "non-dilutive-grant-stacking",
      "name": "Orphan Disease Non-Dilutive Capital & Ethical Community Validation",
      "description": "Lists stackable NIH SBIR/STTR, ARPA-H, MPN Research Foundation, Blood Cancer United TAP, CDCN/Every Cure, and FDA OOPD grants (list_non_dilutive_grants) paired with non-extractive patient-community validation pathways (get_validation_communities).",
      "tags": [
        "grants",
        "SBIR",
        "ARPA-H",
        "non-dilutive",
        "patient-advocacy",
        "ethical-validation"
      ],
      "examples": [
        "List non-dilutive grants and ethical validation communities for a seed-stage myelofibrosis AI drug repurposing team."
      ]
    },
    {
      "id": "query-myelofibrosis-molecular-apis",
      "name": "Query Myelofibrosis Molecular, Structural, Comparison & Catalyst Micro-APIs",
      "description": "Queries zero-auth micro-APIs for single-cell & stromal gene signatures (GET /api/gene?symbol=&cohort=&compartment=&q=), JAK2 V617F JH2 vs WT structural pockets (GET /api/pocket?pdb=&domain=&target=&q=), side-by-side Paired Flagship comparisons (GET /api/compare?a=jak2-myelofibrosis&b=autoimmune-myelofibrosis), and upcoming clinical/regulatory catalysts (GET /feeds/catalysts.json & /feeds/myelofibrosis-catalysts.ics).",
      "tags": [
        "molecular-api",
        "gene-signatures",
        "structural-pockets",
        "compare",
        "catalysts",
        "ics-calendar",
        "JAK2-V617F",
        "AIMF"
      ],
      "examples": [
        "Query GET https://api.rare-disease-atlas.workers.dev/api/gene?symbol=HAMP and /api/pocket?pdb=4FVR.",
        "Compare jak2-myelofibrosis vs autoimmune-myelofibrosis via GET /api/compare and inspect upcoming catalysts in /feeds/catalysts.json."
      ]
    },
    {
      "id": "submit-research-finding-or-benchmark",
      "name": "Two-Way A2A Research Finding Submission & MyelofibrosisBench-v1 Leaderboard",
      "description": "Accepts citation-backed translational findings, clinical trial readouts, or errata over two-way A2A (prefix message with 'submit finding:' \u2014 zero PII, zero auth) and publishes opt-in anonymous MyelofibrosisBench-v1 model evaluations to the live leaderboard (/benchmarks/leaderboard.html & GET /api/leaderboard.json).",
      "tags": [
        "a2a-submission",
        "submit-finding",
        "MyelofibrosisBench-v1",
        "leaderboard",
        "open-science",
        "benchmark"
      ],
      "examples": [
        "submit finding: NCT06313593 Phase 1 JH2 V617F-selective inhibitor biomarker update for jak2-myelofibrosis.",
        "Fetch live standings from https://api.rare-disease-atlas.workers.dev/api/leaderboard.json and submit an anonymous MyelofibrosisBench-v1 evaluation."
      ]
    }
  ]
}